Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis

Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis

Entecavir (ETV) is a first‐line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance. Previous studies revealed that ETV‐resistant (ETVr) HBV DNA resulted from substitutions in the HBV reverse transcriptase (RT) at positions...

Full description

Bibliographic Details
Main Authors: Ronald E. Rose, Dennis Hernandez, Paul J. Falk, Karen Ericson, Nannan Zhou, Alexandra Thiry, Fiona McPhee
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2018-09-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1231

Internet

https://doi.org/10.1002/hep4.1231

Similar Items